- Ticker
- GILD
- Price
- 69.42
- Stock movement down
- -0.16 (-0.23%)
- Company name
- Gilead Sciences Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers-General
- Market cap
- 86.57B
- Ent value
- 123.09B
- Price/Sales
- 3.17
- Price/Book
- 4.08
- Div yield
- 4.44%
- Div growth
- 5.64%
- Growth years
- 6
- FCF payout
- 43.18%
- Trailing P/E
- 18.85
- Forward P/E
- 9.62
- PEG
- 13.47
- EPS growth
- 0.73%
- 1 year return
- -17.01%
- 3 year return
- 1.58%
- 5 year return
- 0.76%
- 10 year return
- -0.63%
Last updated: 2024-04-08
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
Dividend yield - 5y
Loading...
Dividend yield data
| Dividend per share | 3.08 |
| Dividend yield | 4.44% |
| Payout frequency | Quarterly |
| Maximum yield | 5.06% |
| Average yield | 4.07% |
| Minimum yield | 3.24% |
| Discount to avg yield | 8.37% |
| Upside potential | 9.13% |
| Yield as % of max yield | 87.70% |
Yield distribution (inverse percentile) - 5y
Loading...
Yield distribution data
| Dividend yield | 4.44% |
| Current yield distribution | 19.44% |
| Yield at 100% (Min) | 3.24% |
| Yield at 90% | 3.56% |
| Yield at 80% | 3.73% |
| Yield at 50% (Median) | 4.01% |
| Yield at 20% | 4.43% |
| Yield at 10% | 4.66% |
| Yield at 0% (Max) | 5.06% |
Dividend per share
Loading...
Dividend per share data
| Years of growth | 6 years |
| CCC status | Dividend Challenger |
| Dividend per share | 3.08 |
| Payout frequency | Quarterly |
| Ex-div date | 14 Mar 2024 |
| EPS (TTM) | 3.63 |
| EPS (1y forward) | 7.22 |
| EPS growth (5y) | 0.73% |
| EPS growth (5y forward) | 1.40% |
Dividend growth
Loading...
Please create a free account or log in to access this chart
Dividend growth data
| GILD | S&P500 | |
| DGR MR | 2.67% | -16.32% |
| DGR TTM | 2.72% | 4.05% |
| DGR 3 years | 3.32% | 5.24% |
| DGR 5 years | 5.64% | 5.40% |
| DGR 10 years | - | 7.07% |
| DGR 15 years | - | 6.12% |
| Time since last change announced | 76 days |
| EPS growth (5y) | 0.73% |
| EPS growth (5y forward) | 1.40% |
Payout ratio
Loading...
Please create a free account or log in to access this chart
Payout ratio data
| EPS coverage | FCF coverage | |
| TTM | 80.77% | 43.18% |
| Average | - | - |
| Forward | 42.66% | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 18.85 |
| Price to OCF | 9.54 |
| Price to FCF | 10.08 |
| Price to EBITDA | 9.64 |
| EV to EBITDA | 13.70 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.17 |
| Price to Book | 4.08 |
| EV to Sales | 4.51 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.25B |
| EPS (TTM) | 3.63 |
| FCF per share (TTM) | 6.80 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 27.28B |
| Gross profit (TTM) | 21.62B |
| Operating income (TTM) | 7.33B |
| Net income (TTM) | 4.59B |
| EPS (TTM) | 3.63 |
| EPS (1y forward) | 7.22 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 79.26% |
| Operating margin (TTM) | 26.87% |
| Profit margin (TTM) | 16.83% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 5.41B |
| Net receivables | 4.78B |
| Total current assets | 15.23B |
| Goodwill | 8.31B |
| Intangible assets | 28.89B |
| Property, plant and equipment | 0.00 |
| Total assets | 63.17B |
| Accounts payable | 905.00M |
| Short/Current long term debt | 5.67B |
| Total current liabilities | 11.24B |
| Total liabilities | 41.93B |
| Shareholder's equity | 21.24B |
| Net tangible assets | -15.97B |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 9.07B |
| Capital expenditures (TTM) | 728.00M |
| Free cash flow (TTM) | 8.59B |
| Dividends paid (TTM) | 3.71B |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 21.62% |
| Return on Assets | 7.27% |
| Return on Invested Capital | 9.68% |
| Cash Return on Invested Capital | 18.11% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 69.14 |
| Daily high | 69.55 |
| Daily low | 69.05 |
| Daily Volume | 4.58M |
| All-time high | 122.21 |
| 1y analyst estimate | 88.96 |
| Beta | 0.40 |
| EPS (TTM) | 3.63 |
| Dividend per share | 3.08 |
| Ex-div date | 14 Mar 2024 |
| Next earnings date | 25 Apr 2024 |
Downside potential
Loading...
Downside potential data
| GILD | S&P500 | |
| Current price drop from All-time high | -43.20% | -0.85% |
| Highest price drop | -70.83% | -56.47% |
| Date of highest drop | 7 Jun 1994 | 9 Mar 2009 |
| Avg drop from high | -25.44% | -11.35% |
| Avg time to new high | 25 days | 13 days |
| Max time to new high | 2213 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
86.57B
Marketcap category
Large-cap
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Employees
17000
Website
Investor relations
SEC filings
CEO
Daniel O'Day
Country
USA
City
Foster City
Stock type
Common stock
CCC status
Dividend Challenger
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page